NasdaqGM - Nasdaq Real Time Price USD

AC Immune SA (ACIU)

1.6700
+0.0100
+(0.60%)
As of 1:51:55 PM EDT. Market Open.
Currency in CHF All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
28,299
27,309
14,801
3,935
0
Operating Expense
79,979
79,687
68,425
74,782
79,010
Operating Income
-51,680
-52,378
-53,624
-70,847
-79,010
Net Non Operating Interest Income Expense
3,103
3,063
868
-286
5,904
Other Income Expense
-3,503
-1,598
-1,467
393
113
Pretax Income
-52,080
-50,913
-54,223
-70,740
-72,993
Tax Provision
3
3
10
13
3
Net Income Common Stockholders
-52,083
-50,916
-54,233
-70,753
-72,996
Diluted NI Available to Com Stockholders
-52,083
-50,916
-54,233
-70,753
-72,996
Basic EPS
-0.52
-0.51
-0.64
-0.85
-0.97
Diluted EPS
-0.52
-0.51
-0.64
-0.85
-0.97
Basic Average Shares
99,947.7980
99,691.9710
84,694.6160
83,554.4120
74,951.8330
Diluted Average Shares
99,947.7980
99,691.9710
84,694.6160
83,554.4120
74,951.8330
Total Operating Income as Reported
-51,680
-52,378
-53,624
-70,847
-79,010
Total Expenses
79,979
79,687
68,425
74,782
79,010
Net Income from Continuing & Discontinued Operation
-52,083
-50,916
-54,233
-70,753
-72,996
Normalized Income
-49,981.2000
-49,453.8300
-52,890.6950
-71,094.9100
-73,105.6100
Interest Income
3,254
3,196
1,044
69
6,485
Interest Expense
151
133
176
355
581
Net Interest Income
3,103
3,063
868
-286
5,904
EBIT
-51,929
-50,780
-54,047
-70,385
-72,412
EBITDA
-49,711
-48,618
-51,832
-68,026
-70,006
Reconciled Depreciation
2,218
2,162
2,215
2,359
2,406
Net Income from Continuing Operation Net Minority Interest
-52,083
-50,916
-54,233
-70,753
-72,996
Total Unusual Items Excluding Goodwill
-3,503
-1,598
-1,467
393
113
Total Unusual Items
-3,503
-1,598
-1,467
393
113
Normalized EBITDA
-46,208
-47,020
-50,365
-68,419
-70,119
Tax Rate for Calcs
0.0004
0.0001
0.0001
0.0001
0
Tax Effect of Unusual Items
-1,401.2000
-135.8300
-124.6950
51.0900
3.3900
12/31/2021 - 9/23/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ANVS Annovis Bio, Inc.
1.5500
-3.13%
 
ADCT ADC Therapeutics SA
1.2850
+0.39%
 
CADL Candel Therapeutics, Inc.
4.8200
+1.26%
 
ALEC Alector, Inc.
1.1150
+7.23%
 
VTGN Vistagen Therapeutics, Inc.
2.2850
+1.56%
 
GRCE Grace Therapeutics, Inc.
2.7600
-1.43%
 
BMEA Biomea Fusion, Inc.
1.6700
-4.57%
 
ARCT Arcturus Therapeutics Holdings Inc.
11.18
-1.76%
 
ANNX Annexon, Inc.
1.6640
-2.11%
 
LPCN Lipocine Inc.
3.2950
-1.05%